Promethera Attracts Sony Innovation Fund by IGV and Pegasus Tech Ventures as New Investors in Final Closing of Series D. Total amount raised in the Series D reaches €47.2 Million.

December 16th 2019

Promethera® Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced the addition of €7.5 million to its recent €39.7 million Series D financing led by new investors Sony Innovation Fund by IGV and Pegasus Tech Ventures.

Promethera will use the proceeds from the financing to further advance the company’s clinical programs in Non-alcoholic steatohepatitis (NASH) and Acute-on-Chronic Liver Failure (ACLF), as well as to accelerate Promethera’s growth in the Asian markets. The company plans to initiate clinical trials outside Europe in its two lead indications, NASH and ACLF, during the course of 2020. Please discover the press release here.